Ondansetron is a potent and highly selective 5HT3 – receptors antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine by activating the vagal afferents via 5HT3 – receptors. Ondansetron blocks the initiation of this reflex.
Indication
Onda is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of postoperative nausea and vomiting (PONV).
In the pediatric population, Onda is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged 6 months, and for the prevention and treatment of PONV in children aged 1 month.